Bavencio (avelumab) plus Inlyta (axitinib) | Friends of Cancer Research

You are here

Bavencio (avelumab) plus Inlyta (axitinib)

Sponsor: 
EMD Serono Inc.
Indication: 
First-line treatment of patients with advanced renal cell carcinoma (RCC)
Category: 
Year: 
2017
Date: 
Dec 22nd
FDA Status: 
FDA Approval
Approval Date: 
May 14th
Approval Year: 
2019